Urologic Cancer clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
open to eligible people ages 18 years and up
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Orange, California and other locations
Our lead scientists for Urologic Cancer research studies include Edward Uchio, MD.
Last updated: